Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 8,686 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Longitudinal Studies Clear all

Conditions: Deep Dental Caries
Interventions: Indirect Pulp capping-Resin-modified calcium silicate - TheraCal, Indirect Pulp capping-Calcium hydroxide - Dycal, Indirect Pulp capping-Resin-based dentin bonding agent, Direct Pulp capping-Resin-modified calcium silicate - TheraCal, Direct Pulp capping-Calcium hydroxide - Dycal; Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 64 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anesthesia
Interventions: MTPI, Classic Induction; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Interventions: EsoCheck®, EsoGuard®; Device · Diagnostic Test
Lead sponsor: Lucid Diagnostics, Inc.; Industry
Eligibility: Not listed
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lake Forest, California

Conditions: Psoriasis (PsO)
Interventions: Deucravacitinib, Other systemic treatments for PsO; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Female only
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Immunosuppression
Interventions: Tacrolimus, combination therapy; Drug
Lead sponsor: Newark Beth Israel Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 2
States / cities: Newark, New Jersey • New York, New York

Conditions: Car Seat Transition for At-risk Infants
Interventions: Measure infant's jaw, record all information about car seat testing, and administer questionnaires.; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Day to 1 Year
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stenosis, Spondylolisthesis, Degenerative Disc Disease
Interventions: Posterior Lateral Fusion (PLF), Anterior Lumbar Interbody Fusion (ALIF), Transforaminal lumbar interbody fusion (TLIF), Posterior lumbar interbody fusion (PLIF), Extreme lateral interbody fusion (XLIF); Procedure
Lead sponsor: Exactech; Industry
Eligibility: 21 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 6
States / cities: Long Beach, California • San Diego, California • New Hartford, New York + 3 more

Conditions: Ulcerative Colitis
Interventions: MMX mesalamine/ mesalazine; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 34
States / cities: Birmingham, Alabama • Anaheim, California • Garden Grove, California + 30 more

Conditions: Lung Transplantation Rejection
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Durham, North Carolina • Research Triangle Park, North Carolina

Conditions: Burn Injury
Interventions: Treatment; Other
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: 1 Month to 18 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Prostate Cancer
Interventions: Survey; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 1,139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Xerostomia
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Mucopolysaccharidosis Type IIIB, Mucopolysaccharidosis Type 3 B, MPS III B, MPS 3 B
Interventions: Not listed
Lead sponsor: Allievex Corporation; Industry
Eligibility: 1 Year to 10 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Oakland, California

Conditions: Anesthetic Effectiveness
Interventions: Articaine Hydrochloride + Epinephrine, Buffered Articaine Hydrochloride + Epinephrine; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Early Alzheimers Disease
Interventions: buntanetap/posiphen, Placebo; Drug
Lead sponsor: Annovis Bio Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 78
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 72 more

Conditions: NSCLC, Melanoma
Interventions: Not listed
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Migraine
Interventions: Not listed
Lead sponsor: Rowan University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Stratford, New Jersey

Conditions: Cerebral Hemorrhage, Brain Hemorrhage, Cerebral Parenchymal Hemorrhage, Intracerebral Hemorrhage
Interventions: Artemis + Medical Management, Best Medical Management Alone (MM); Device · Other
Lead sponsor: Penumbra Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 27
States / cities: Phoenix, Arizona • Los Angeles, California • Mission Viejo, California + 22 more

Conditions: Major Depressive Disorder
Interventions: Brainsway Deep TMS System; Device
Lead sponsor: Brainsway; Industry
Eligibility: 22 Years to 68 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Tuscaloosa, Alabama • Redlands, California • Palm Beach, Florida + 4 more

Conditions: Ear Barotrauma, Middle Ear Disease, Ear Diseases, Pressure Injury, Eustachian Tube Dysfunction, Middle Ear; Injury, Middle Ear Barotrauma
Interventions: Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw), Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw); Procedure
Lead sponsor: Northwell Health; Other
Eligibility: Not listed
Enrollment: 1,553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Sleepy Hollow, New York

Conditions: Hernia, Inguinal
Interventions: ULTRAPRO Mesh, 3DMAX, Evaluation; Device · Other
Lead sponsor: South East Area Health Education Center, Wilmington, NC; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Hip Fractures, Pain, Acute
Interventions: Pericapsular Nerve Group Block; Procedure
Lead sponsor: Jacobi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Alport Syndrome, Kidney Disease
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: Up to 18 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions: Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging of the Heart; Drug · Procedure
Lead sponsor: Seema Bhat; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Clinical Comparison of Vital Pulp Capping Restorative Protocols

Intubation Conditions Achieved With Rapid Co-administration of Rocuronium and Propofol Versus Classical Induction

Lucid Registry Study

A Study to Assess Deucravacitinib Safety in Pregnancy

Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients

Infant Transition From Car Bed to Car Safety Seat

Evaluation of Radiographic and Patient Outcomes Following Lumbar Spine Fusion Using Demineralized Bone Matrix (DBM) Mixed With Autograft

Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

Prospective Lung Transplant Database for Genetic Research

Transfusion Ratio of Fresh Frozen Plasma (FFP) to Packed Red Blood Cell (PRBC) During Burn Excision and Grafting

Active Surveillance in Prostate Cancer

Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation

A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

Testing the Anesthetic Effectiveness of Buffered Articaine Injected Next to a Lower First Molar.

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care

The Evolution and Management of Migraine Recurrence Beyond 24 Hours

MIND: Artemis in the Removal of Intracerebral Hemorrhage

New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)

Effect of Rate (Slope) of Compression on the Incidence of Symptomatic ETD and MEB: a Phase III Prospective Study.

Prospective Trial Comparing Two Different Polypropylene Meshes for Inguinal Hernias

Pericapsular Nerve Group Block for Hip Fractures

A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma